NEW YORK, May 11, 2021 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Repro Med Systems, Inc. d/b/a KORU Medical Systems («KORU» or the «Company») (NASDAQ: KRMD) and certain of its officers. The class action, filed in the United States District Court for Southern District of New York, and docketed under 21-cv-04109, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired KORU securities between August 4, 2020 and January 25, 2021, inclusive (the «Class Period»). Plaintiff pursues claims against the Defendants under the Securities Exchange Act of 1934 (the «Exchange Act»).
If you are a shareholder who purchased KORU securities during the Class Period, you have until May 25, 2021 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at email@example.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
KORU designs, manufactures, and markets proprietary portable medical devices, primarily for the ambulatory infusion market.
The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) starting in January 2020, KORU ramped up the use of allowances, including growth rebates, to retain key customers and to incentivize growth; (2) as the rebates accrued, the Company’s net sales were reasonably likely to decline; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
On November 3, 2020, after the market closed, KORU announced its third quarter 2020 financial results, reporting that net sales declined sequentially to $6.1 million. During a conference call the next day, the Company attributed the lower sales to, among other things, «higher allowances for gross rebates for certain customers» and «payment discounts and distribution fees.»
On this news, the Company’s stock fell $1.97, or 32%, to close at $4.16 per share on November 4, 2020, on unusually heavy trading volume.
On January 25, 2021, after the market closed, KORU announced its preliminary financial results for fiscal 2020, expecting revenue of approximately $24.0 million, an increase of 3.4% over the prior year. The Company attributed the results to, among other things, «[s]lower growth in net revenue as a result of strengthening our contractual position with large customers.» In the press release, KORU also announced that its CEO, Donald Pettigrew, resigned, effective immediately.
On this news, KORU’s stock price fell $0.80 per share, or 15.5%, to close at $4.33 per share on January 26, 2021, on unusually heavy trading volume.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
Robert S. Willoughby
888-476-6529 ext. 7980
View original content to download multimedia:http://www.prnewswire.com/news-releases/pomerantz-law-firm-announces-the-filing-of-a-class-action-against-repro-med-systems-inc-dba-koru-medical-systems-and-certain-officers–krmd-301289222.html
SOURCE Pomerantz LLP